Regina Crespo Lopez Oliver

Regina Crespo Lopez Oliver

ITESM, Campus Monterrey, Monterrey, Nuevo León, Mexico

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2023 in Bioengineering
Verified
Journal Article
Open access
PDF file
Mónica Gabriela Sánchez SalazarMónica Gabriela Sánchez Salazar
Mónica Gabriela Sánchez Salazar
Regina Crespo Lopez OliverRegina Crespo Lopez Oliver
Regina Crespo Lopez Oliver
SMSofia Ramos Meizoso
Sofia Ramos Meizoso
Valeri Sofia Jerezano FloresValeri Sofia Jerezano Flores
Valeri Sofia Jerezano Flores
SGSalvador Gallegos-Martínez
Salvador Gallegos-Martínez
Mario Moisés AlvarezMario Moisés Alvarez
Mario Moisés Alvarez
Tumor-on-chips have become an effective resource in cancer research. However, their widespread use remains limited due to issues related to their practicality in fabrication and use. To address some of these limitations, we introduce a 3D-printed chip, which is large enough to host ~1 cm3 of tissue and fosters well-mixed conditions in the liquid niche, while still enabling the formation of the concentration profiles that occur in real tissues due to diffusive transport. We compared the mass transport performance in its rhomboidal culture chamber when empty, when filled with GelMA/alginate hydrogel microbeads, or when occupied with a monolithic piece of hydrogel with a central channel, allowing communication between the inlet and outlet. We show that our chip filled with hydrogel microspheres in the culture chamber promotes adequate mixing and enhanced distribution of culture media. In proof-of-concept pharmacological assays, we biofabricated hydrogel microspheres containing embedded Caco2 cells, which developed into microtumors. Microtumors cultured in the device developed throughout the 10-day culture showing >75% of viability. Microtumors subjected to 5-fluorouracil treatment displayed <20% cell survival and lower VEGF-A and E-cadherin expression than untreated controls. Overall, our tumor-on-chip device proved suitable for studying cancer biology and performing drug response assays.